Genomics and Molecular Resources Core

项目概要/摘要-基因组学和分子资源核心 我们中心的总体目标是推进风湿性疾病的精准医学。基因组学和 分子资源（GMR）核心将通过促进生物标本的获取在我们的中心发挥关键作用 从特征明确的风湿病患者，并提供咨询和协调服务， 确保适当使用基因组学、蛋白质组学和其他有潜力的分子技术， 推进风湿病学的精准医疗。GMR Core将简化实验室研究 基础设施，包括生物标本的采集、处理、储存和管理， 加州大学旧金山分校现有的风湿病生物标本并建立最先进的实验室信息 管理系统（LIMS），这将使我们能够扩大样本收集，并建立一个可访问的 生物储藏室这些活动将在GMR联席主任郭培仁博士的实验室内进行 核心，其作为UCSF基因组学核心在过去十年的教师主任的经验，使他 非常有资格指导这些活动。核心领导还将提供与 适当应用基因组学和分子测定（包括蛋白质组学和免疫表型） 并将作为研究者和实验室人员之间的联络人，以确保持续的高 获得高质量的基因组和分子表型数据。一组基因组学和分子生物学 表型专家将担任P30研究者和项目的顾问，涵盖广泛的领域， 专业知识，包括基因组学，表观遗传学，蛋白质组学，免疫表型，淋巴细胞信号， 微生物组分析和多能干细胞的产生。GMR核心将与 人类受试者和临床表型分析（HSCP）核心，以协调选择适当的风湿性关节炎 中心研究的疾病患者和临床数据，以及整合生物信息学（IB）核心， 将基因组和分子数据与临床数据整合用于统计分析。GMR核心的主要优势 包括大量现有的风湿性疾病生物标本，这些标本将被合并并集中在 使用最先进的LIMS进行管理;国际知名的基因组学和分子生物学专家 风湿性、自身免疫性和其他疾病的表型分析;产生最先进基因组学的设施 以及来自人类生物标本的其他分子表型数据;以及在当地、全国和 促进中心的外展活动，以推进风湿病的精准医学 research.

PROJECT SUMMARY/ABSTRACT – Genomics and Molecular Resources Core The overall goal of our Center is to advance precision medicine in the rheumatic diseases. The Genomics and Molecular Resources (GMR) Core will play a critical role in our Center by facilitating access to biospecimens from well-characterized rheumatic disease patients, and providing consultative and coordination services to ensure appropriate use of genomics, proteomics, and other molecular technologies that have the potential to advance precision medicine in rheumatology. The GMR Core will streamline laboratory research infrastructure, including acquisition, processing, storage and management of biospecimens by consolidating existing rheumatology biospecimens at UCSF and establishing a state-of-the-art Laboratory Information Management System (LIMS) that will enable us to expand sample collection and create an accessible biorepository. These activities will occur within the laboratory of Dr. Pui-Yan Kwok, Co-Director of the GMR Core, whose experience as Faculty Director of the UCSF Genomics Core over the past decade makes him highly qualified to direct these activities. Core leadership will also provide consultation related to the appropriate application of genomics and molecular assays (including proteomic and immunologic phenotyping) and will serve as a liaison between investigators and laboratory personnel to ensure that consistently high quality genomic and molecular phenotyping data are obtained. A panel of genomics and molecular phenotyping experts will serve as consultants for P30 investigators and projects, covering a wide range of expertise including genomics, epigenetics, proteomics, immune phenotyping, lymphocyte signaling, microbiome analysis, and production of pluripotent stem cells. The GMR Core will work closely with the Human Subjects and Clinical Phenotyping (HSCP) Core to coordinate selection of the appropriate rheumatic disease patients and clinical data for Center studies, and with the Integrative Bioinformatics (IB) Core to integrate genomic and molecular data with clinical data for statistical analysis. Key strengths of the GMR Core include the substantial existing rheumatic disease biospecimens that will be consolidated and centrally managed using a state-of-the-art LIMS; internationally renowned experts in genomics and molecular phenotyping for rheumatic, autoimmune and other disorders; facilities for generating state-of-the-art genomics and other molecular phenotyping data from human biospecimens; and visibility locally, nationally, and internationally to facilitate outreach activities of the Center to advance precision medicine in rheumatic disease research.